Will the Real Sequenom SEQureDx Please Stand Up?

In an SEC filing today, Sequenom said it "believes" last week's letter from the FDA refers to its fetal RhD-genotyping test. Trouble is, RhD status doesn't signify a "gene and chromosome abnormality," which is how FDA characterized the mystery test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.